In This Article:
-
Net Loss (Q4 2024): $9.6 million or $1.25 per share.
-
Net Loss (Q4 2023): $117 million or $2.03 per share.
-
Net Loss (FY 2024): $43.4 million or $6.88 per share.
-
Net Loss (FY 2023): $47.4 million or $8.96 per share.
-
Research and Development Expenses (Q4 2024): $9 million.
-
Research and Development Expenses (Q4 2023): $10 million.
-
Research and Development Expenses (FY 2024): $38.6 million.
-
Research and Development Expenses (FY 2023): $39.5 million.
-
General and Administrative Expenses (Q4 2024): $3.4 million.
-
General and Administrative Expenses (Q4 2023): $4.9 million.
-
General and Administrative Expenses (FY 2024): $16.8 million.
-
General and Administrative Expenses (FY 2023): $18.6 million.
-
Net Proceeds from October Offering: Approximately $10.8 million.
-
Gross Proceeds from March Offering: Approximately $10 million.
-
Cash Runway: Extended into the fourth quarter of 2025.
Release Date: March 31, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Curis Inc (NASDAQ:CRIS) received encouraging feedback from the EMA and FDA on the potential for conditional marketing authorization in Europe and accelerated approval in the US for their TakeAim lymphoma study.
-
The TakeAim lymphoma study is now considered registrational for both the US and Europe, accelerating the development timeline for emavusertib.
-
Emavusertib has been granted orphan drug designation for primary CNS lymphoma in both the US and Europe.
-
The clinical data for emavusertib in combination with ibrutinib showed promising results, with significant tumor burden reduction and objective responses in both BTKi-experienced and BTKi-naive PCNSL patients.
-
Curis Inc (NASDAQ:CRIS) reported a decrease in net loss and reduced R&D and G&A expenses compared to the previous year, indicating improved financial management.
Negative Points
-
Curis Inc (NASDAQ:CRIS) reported a net loss of $9.6 million for the fourth quarter of 2024, highlighting ongoing financial challenges.
-
The company continues to face risks and uncertainties related to forward-looking statements and actual results may differ materially.
-
The cash runway has been extended only until the fourth quarter of 2025, indicating potential future funding needs.
-
There is uncertainty regarding the number of patients needed to meet FDA requirements for individual component contributions in the emavusertib study.
-
The company is still in the early stages of discussions with potential partners, indicating that strategic partnerships are not yet secured.